Physician profile
Young-Jik Lee
NPI 1447271036
$15,049.41
in general payments reported to CMS, 2019-2025
53 companies · $1,520 in 2025
The $1,520 reported for 2025 was more than what 90% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,757 · 2020: $2,440 · 2021: $3,165 · 2022: $1,618 · 2023: $1,182 · 2024: $1,366 · 2025: $1,520.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,069.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,068.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,844.65 | 2019-2025 | Breztri, Farxiga, Lokelma |
| Abbvie INC. | $1,629.79 | 2019-2025 | |
| Amgen INC. | $1,520.92 | 2019-2025 | Evenity, Prolia, Repatha |
| Glaxosmithkline, LLC. | $1,459.59 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amarin Pharma, INC. | $1,041.36 | 2019-2023 | |
| Pfizer INC. | $841.13 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $657.44 | 2019-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $643.21 | 2021-2025 | |
| Novo Nordisk INC | $532.70 | 2019-2022 | |
| Lilly USA, LLC | $464.92 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $399.96 | 2019-2021 | |
| Gilead Sciences, INC. | $355.01 | 2019-2025 | |
| Scilex Pharmaceuticals INC. | $331.55 | 2019-2023 | Ztlido |
| Nestle Healthcare Nutrition INC. | $302.55 | 2020-2023 | |
| Ardelyx, INC. | $248.58 | 2024-2025 | Ibsrela |
Show all 53 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $230.09 | 2019-2023 | Januvia, Steglatro, Belsomra |
| Ironwood Pharmaceuticals, INC | $214.43 | 2021-2024 | Linzess |
| Janssen Pharmaceuticals, INC | $181.77 | 2019-2021 | |
| Sumitomo Pharma America, INC. | $173.10 | 2024-2025 | Gemtesa |
| Allergan, INC. | $172.82 | 2019-2020 | |
| Radius Health, INC. | $158.62 | 2021 | |
| Eisai INC. | $145.01 | 2020-2025 | |
| Novartis Pharmaceuticals Corporation | $138.27 | 2019-2024 | |
| Astellas Pharma US INC | $128.08 | 2019-2021 | |
| Aimmune Therapeutics, INC. | $102.55 | 2024-2025 | Zenpep |
| Exact Sciences Corporation | $102.11 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Otsuka America Pharmaceutical, INC. | $79.99 | 2023-2024 | Rexulti |
| Almatica Pharma LLC | $79.25 | 2022-2024 | Loreev Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $73.66 | 2019-2020 | |
| Vivus LLC | $63.89 | 2023-2024 | Pancreaze |
| Ibsa Pharma INC. | $56.02 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $55.70 | 2021-2022 | |
| Phathom Pharmaceuticals, INC. | $53.84 | 2024-2025 | Voquezna |
| Alvogen INC | $48.15 | 2023-2024 | Teriparatide |
| Dexcom, INC. | $41.83 | 2021-2024 | Dexcom G6 Transmitter |
| Genentech USA, INC. | $40.28 | 2021 | |
| Teleflex LLC | $36.82 | 2025 | Urolift |
| Redhill Biopharma INC. | $36.27 | 2020-2021 | |
| Arbor Pharmaceuticals, INC. | $29.75 | 2020-2021 | |
| Alnylam Pharmaceuticals INC. | $29.57 | 2022 | |
| Insmed, INC. | $29.01 | 2025 | Brinsupri, Arikayce |
| Shield Therapeutics INC | $27.41 | 2024 | |
| Grifols USA, LLC | $24.77 | 2019 | |
| Lundbeck LLC | $24.54 | 2023 | Rexulti |
| Corium, LLC | $24.18 | 2022 | |
| Sunovion Pharmaceuticals INC. | $24.17 | 2021 | |
| Xeris Pharmaceuticals, INC. | $23.37 | 2021 | |
| Sanofi-Aventis U.S. LLC | $23.00 | 2019 | |
| Esperion Therapeutics, INC. | $21.74 | 2021 | |
| Hikma Pharmaceuticals USA | $21.67 | 2021 | |
| Eyevance Pharmaceuticals LLC | $21.67 | 2021 | |
| Abbott Laboratories | $20.82 | 2025 | Freestyle Libre 3 |
| Mylan Specialty L.P. | $17.83 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Young-Jik Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.